Published in J Mol Endocrinol on October 13, 2008
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2015) 1.47
Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol (2015) 1.02
Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia. Compr Physiol (2014) 0.88
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res (2014) 0.82
Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab (2011) 0.79
Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome. Case Rep Endocrinol (2016) 0.75
[Cushing's syndrome. I. New diagnostic developments]. Ned Tijdschr Geneeskd (2006) 2.73
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Octreotide. N Engl J Med (1996) 2.67
Field study of the prevalence of lameness in horses with back problems. Vet Rec (2004) 2.11
Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med (1994) 1.93
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab (1990) 1.71
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2003) 1.66
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology (1995) 1.54
[Irreversible coma following hypoglycemia in Sheehan syndrome with adrenocortical insufficiency]. Ned Tijdschr Geneeskd (2003) 1.49
Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. J Clin Endocrinol Metab (2009) 1.49
[Cushing's syndrome. II. New forms of treatment]. Ned Tijdschr Geneeskd (2006) 1.47
The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH-secreting pituitary adenomas. Clin Endocrinol (Oxf) (1991) 1.39
[Prolactinoma; diagnosis and treatment]. Ned Tijdschr Geneeskd (1996) 1.37
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer (2003) 1.32
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab (2004) 1.28
Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab (2005) 1.22
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci (1991) 1.20
Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab (2008) 1.18
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet (2005) 1.18
Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol (2003) 1.17
A novel tool in the diagnosis and follow-up of (cyclic) Cushing's syndrome: measurement of long-term cortisol in scalp hair. J Clin Endocrinol Metab (2012) 1.14
Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol (2008) 1.14
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res (1998) 1.13
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets (2009) 1.10
Neuroendocrine tumor markers. Front Neuroendocrinol (2001) 1.08
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med (1995) 1.08
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab (2008) 1.05
Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab (2011) 1.04
Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer (2005) 1.02
Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes. Br J Ophthalmol (2004) 1.02
Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol (2012) 1.00
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol (2013) 1.00
Somatostatin and somatostatin receptors in the immune system: a review. Eur Cytokine Netw (2000) 1.00
Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab (2008) 0.99
Cerebrospinal fluid leakage during transsphenoidal surgery: postoperative external lumbar drainage reduces the risk for meningitis. Pituitary (2004) 0.98
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol (2009) 0.98
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) (2013) 0.97
Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum. J Pathol (2001) 0.97
Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest (2005) 0.96
Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med (1995) 0.94
Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. Growth Horm IGF Res (2010) 0.94
Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab (2011) 0.93
Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway. Am J Physiol Endocrinol Metab (2007) 0.93
Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol (2000) 0.93
A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clin Endocrinol (Oxf) (2004) 0.93
Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol (1993) 0.91
Ethnic differences in outcomes of diabetes care and the role of self-management behavior. Patient Educ Couns (2008) 0.91
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. J Clin Endocrinol Metab (2008) 0.91
Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol (1993) 0.91
Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest (2005) 0.91
Diagnosis and treatment of acromegaly complications. J Endocrinol Invest (2003) 0.90
Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide. Int J Cancer (1995) 0.90
Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Br J Surg (1994) 0.90
Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab (2004) 0.90
Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2014) 0.89
5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. Bone (2012) 0.89
Diagnosis and treatment of hypopituitarism: an update. Pituitary (2005) 0.89
Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci (2007) 0.89
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab (2012) 0.89
Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Rev Endocr Metab Disord (2008) 0.88
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly. Diabetologia (2012) 0.88
Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J Clin Endocrinol Metab (2001) 0.88
The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol (2002) 0.87
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Eur J Endocrinol (2001) 0.87
The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol (2002) 0.87
New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol (2002) 0.87
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer (1999) 0.86
Igf-I and longevity. Horm Res (2004) 0.86
Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests. Eur J Endocrinol (2014) 0.85
Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer (1999) 0.85
New developments in the medical treatment of Cushing's syndrome. Endocr Relat Cancer (2012) 0.84
Somatostatin receptor distribution and function in immune system. Dig Liver Dis (2004) 0.84
Cushing's disease in dogs and humans. Horm Res (2009) 0.84